Designing and Development of a DNA Vaccine Based On Structural Proteins of Hepatitis C Virus.

Roghayeh Teimourpour, Amineh Sadat Tajani, Vahid Reza Askari, Sina Rostami, Zahra Meshkat

Abstract read

In one paragraph

Article in Iranian journal of pathology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

0.2field-weighted citation impact, top 43% of its field

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 3 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 3 institutions in 2 countries.

Roghayeh TeimourpourDepartment of Microbiology, School of Medicine, Ardabil University of Medical Sciences, Ardabil, Iran.

Amineh Sadat TajaniPharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran.

Vahid Reza AskariPharmacy School, Mashhad University of Medical Sciences, Mashhad, Iran.

Sina RostamiThe Influenza Centre, Department of Clinical Science, University of Bergen, N-5021 Bergen, Norway.

Zahra MeshkatAntimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran.

Mashhad University of Medical Sciences · IRArdabil University of Medical Sciences · IRUniversity of Bergen · NO

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis C virus (HCV) infection is one of the most prevalent infectious diseases responsible for high morbidity and mortality worldwide. Therefore, designing new and effective therapeutics is of great importance. The aim of the current study was to construct a DNA vaccine containing structural proteins of HCV and evaluation of its expression in a eukaryotic system.

methodsStructural proteins of HCV (core, E1, and E2) were isolated and amplified from

resultsA recombinant vector containing 2241bp fragment of HCV structural genes was constructed. The desired plasmid was sequenced and corresponded to 100% identity with the submitted sequences in GenBank. RT-PCR results indicated that the recombinant plasmid could be expressed efficiently in the eukaryotic expression system.

conclusionSuccessful cloning of structural viral genes in pCDNA3.1 (+) vector and their expression in the eukaryotic expression system facilitates the development of new DNA vaccines against HCV. A DNA vaccine encoding core-E1-E2 antigens was designed. The desired expression vector can be used for further attempts in the development of vaccines.

Indexed as

DNA VaccineHCVStructural proteins

Identifiers

PMID27799971

PMCPMC5079455

OpenAlexW2338933298

What OpenQuestion holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.